Abstract:Multiple myeloma (MM) is an incurable B-cell malignancy. High-dose chemotherapy with stem cell support has achieved higher response rates than conventional therapy, but few patients remain in long-term remission. Arsenic trioxide (As2O3) is an effective treatment for acute promyelocytic leukemia. Current clinical studies are investigating arsenic as a therapeutic agent for malignancies. The mechanism of cytotoxicity inducted by As2O3 has not been known thoroughly. Constitutively activated NF-κB is a characteristic of different tumor entities including MM clones and malignant plasma cells from MM patients. It plays an important role in maintaining tumor cell proliferation and protecting cell from apoptosis. The study was to explore the possible mechanism of As2O3 effects on MM lines. Materials and methods: The human MM cell lines of KM3 and RPMI8226 were provided by Hematology Institution of Zhejiang University. The concentration of As2O3 in cell culture system was from 0.5μmol/L to 20μmol/L, 24 hours was selected as the termination point of cell culture. Cell culture without As2O3 and first-antibody-dismissed test were enrolled as controls. Both of the MM lines were treated with As2O3 in various concentrations. The restrained proliferation was observed by drawing growth curve. MTT bioassay was used to examine the effect of As2O3 on cell growth and the concentration of 50% growth inhibition( IC50) calculated respectively. Apoptosis and changes of IκB-α protein was observed by flow cytometry(FCM). Changes and subcellular localization of IκB-α protein were observed by fluorescence microscopy. Western blot was also used to analyze the expression of NF-κB in nuclear. Results: As2O3 inhibited the proliferation of both MM lines, and IC50 of KM3 and RPMI8226 was 9.61μmol/L and 8.01μmol/L respectively. After exposure to As2O3, both of the lines were induced to apoptosis. With As2O3 concentration varied from 0.5μmol/L to 20μmol/L the apoptosis rate of KM3 and RPMI8226 was concentration-dependent measured by FCM. After 24 hours treated with 20μmol/L As2O3, the apoptosis rate of KM3 cells was 41.18% while that of RPMI8226 was 65.25%. It seemed that RPMI8226 cell was more sensitive to As2O3. FCM analysis showed a significant increase in the percentage of G2/M phase cells, from 13.74% to 41.72%, and a decrease percentage of S phase cells from 35.11% to 23.96%. The level of IκB-α in cytoplasm was down-regulated after As2O3 stimulation in both cell lines. The down-regulation of IκB-α from 79.68% to 51.57% was confirmed by FCM in KM3 treated with 10μmol/L As2O3 (p<0.01), the effect was concentration-dependent. While the IκB-α in RPMI8226 changed from 79.72% to 34.08% (p<0.01). Immunofluorescence assay showed that IκB-α localized in cytoplasm mostly. The level of IκB-α protein was down-regulated after As2O3 stimulation. The results showed that KM3 and RPMI8226 lines expressed constitutively activity NF-κB and As2O3 down-regulated the constitutive expression of NF-κB in both cell lines but with different kinetics. Conclusions: As2O3 could not only inhibit the proliferation but also induce apoptosis of KM3 and RPMI8226 cells. The mechanisms of its effect on MM cells may include decreasing the constitutive activity of NF-κB, subsequently down-regulating the expression of various gene products controlled by NF-κB, thus inducing apoptosis in MM cells. As2O3 could inhibit the proliferation of MM cells by changing MM cell cycle and inducing G2/M phase arrest.

Triptolide Inhibits Transcription Factor Nf-Kappab and Induces Apoptosis of Multiple Myeloma Cells

Triptolide Down-regulates Bcr-abl Expression and Induces Apoptosis in Chronic Myelogenous Leukemia Cells

Triptolide Inhibits the Proliferation of Cells from Lymphocytic Leukemic Cell Lines in Association with Downregulation of NF-κB Activity and Mir-16-1*.

Inhibition of Hsp90 by Triptolide (tpl) Augments Bortezomib-Induced U266 Cells Apoptosis

Triptolide Enhances the Sensitivity of Multiple Myeloma Cells to Dexamethasone Via Micrornas.

Mechanism Of Arsenic Trioxide-Induced Apoptosis On Multiple Myeloma Cells.

Triptolide Induces Apoptosis in Myelodysplastic Syndromes MUTZ-1 Cells Through Activation of Caspases and Down-Regulation of IAPs

[Study of Triptolide-Induced Apoptosis in MUTZ-1 Cells and Its Allied Mechanism].

Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells

Triptolide Overcomes Dexamethasone Resistance and Enhanced PS-341-induced Apoptosis Via PI3k/Akt/NF-kappaB Pathways in Human Multiple Myeloma Cells.

Triptolide Shows High Sensitivity and Low Toxicity Against Acute Myeloid Leukemia Cell Lines Through Inhibiting WSTF-RNAPII Complex

Berbamine, a Novel Nuclear Factor Κb Inhibitor, Inhibits Growth and Induces Apoptosis in Human Myeloma Cells

[Berbamine induces apoptosis of multiple myeloma RPMI 8226 cells by activating GADD45/JNK pathway].

Polyphyllin I Induces Cell Cycle Arrest and Apoptosis in Human Myeloma Cells Via Modulating Β‐catenin Signaling Pathway

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells

Triptolide Inhibits Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Expression in Human Colon Cancer and Leukemia Cells

Tripterine Induces Apoptosis of Human Acute Myelocytic Leukemic Cells Via Up-Regulating Fas/FasL and Down-Regulating NF-κB

Triptolide induces apoptosis in human leukemia cells through caspase-3-mediated ROCK1 activation and MLC phosphorylation

Daptomycin Inhibits Multiple Myeloma Progression through Downregulating the Expression of RPS19

Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation